What is Micell Technologies?
Micell Technologies operates at the intersection of material science and cardiovascular medicine. The company is primarily recognized for its proprietary supercritical fluid technology, which facilitates the creation of sophisticated drug-eluting medical devices. Its flagship product, the MiStent SES, represents a significant leap forward in addressing the limitations of traditional stent technology. By optimizing drug delivery, Micell aims to improve patient outcomes and reduce the complications associated with cardiovascular interventions. Currently, the company maintains a strong international presence, with its products available in various global markets, although it remains focused on navigating the complex regulatory pathways required for broader expansion, including potential entry into the United States market.
How much funding has Micell Technologies raised?
Micell Technologies has raised a total of $119.3M across 4 funding rounds:
Private Equity
$25.8M
Multiple Rounds
$93.5M
Private Equity (2016): $25.8M, investors not publicly disclosed
Private Equity (2017): $31.8M, investors not publicly disclosed
Private Equity (2017): $41.8M, investors not publicly disclosed
Private Equity (2017): $20M, investors not publicly disclosed
Key Investors in Micell Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Micell Technologies?
With this major enterprise-level funding, Micell Technologies is well-positioned to accelerate its research and development initiatives. The strategic allocation of this capital will likely focus on scaling manufacturing capabilities and expanding the clinical evidence base for its drug-eluting platforms. As the company matures, stakeholders will be monitoring its ability to penetrate new geographic territories and further refine its supercritical fluid applications. The focus remains on long-term value creation through technological differentiation and the pursuit of regulatory milestones that will solidify its market position as a leader in cardiovascular innovation.
See full Micell Technologies company page
